Baxter Redaction and InterestThe only customer is Baxter. They have exclusivity for distribution of PMX and the EAA. They have already started the marketing program so that upon approval from the FDA they can hit the ground running. The only reason for Spectral to market more broadly is to gain wider interest in Spectral stock with a view to the stock price moving towards it's true value. Something the BOD and management have not done very well or at all from my observations.
Baxter is the key. We have no idea what the deal with them is. If it was just a series of milestone payments the need for redaction - if there ever was a need - has long passed. It just isn't a valid reason for witholding the information for almost four years now. Therefore, there must be something else in the deal that is redactionworthy. And since we're exceeding expectations on 72 enrolled on the way to 90 enrolled that milestone is effectively achieved - only timing to be determined and that will be by the end of 2023. I wouldn't be surprised to see Baxter - or KidneyCo - take over the trial at that stage through a buyout of Spectral. I think the time is drawing near and Spectral has no choice but to get to 90 enrolled by the end of this year. At which time I'm guessing we may see what is under that redaction ink after four years. And hopefully the payday we've all been waiting for.